l e t t e r s
Paget's disease of bone (PDB) is a common disorder with a strong genetic component characterized by focal increases in bone turnover, which in some cases is caused by mutations in SQSTM1. To identify additional susceptibility genes, we performed a genome-wide association study in 750 individuals with PDB (cases) without SQSTM1 mutations and 1,002 controls and identified three candidate disease loci, which were then replicated in an independent set of 500 cases and 535 controls. The strongest signal was with rs484959 on 1p13 near the CSF1 gene (P = 5.38 × 10 −24 ). Significant associations were also observed with rs1561570 on 10p13 within the OPTN gene (P = 6.09 × 10 −13 ) and with rs3018362 on 18q21 near the TNFRSF11A gene (P = 5.27 × 10 −13 ). These studies provide new insights into the pathogenesis of PDB and identify OPTN, CSF1 and TNFRSF11A as candidate genes for disease susceptibility.
PDB is a common disorder of the skeleton that affects up to 2% of individuals of European ancestry aged 55 years and above 1 . The disease is characterized by focal areas of increased and disorganized bone remodeling that can cause bone pain, bone deformity, pathological fracture, deafness and secondary osteoarthritis 2 . Genetic factors are important contributors to PDB risk, and between 15% and 40% of individuals with PDB have an affected first-degree relative 3 . Mutations affecting the ubiquitin-associated domain of SQSTM1 have been identified in about 10% of individuals with what is termed 'sporadic' PDB and in about 40% of individuals with familial PDB 4, 5 . Despite extensive research efforts and the identification of several susceptibility loci by linkage analysis [6] [7] [8] , the remaining genes that predispose to PDB have yet to be identified.
In this study, we sought to identify genetic variants that predispose to PDB in individuals without SQSTM1 mutations by using a genomewide association approach. In the discovery population (stage 1), we genotyped 750 cases and 1,002 controls 9 using Illumina arrays. In the replication population (stage 2), we genotyped the most significant SNPs identified from stage 1 in an independent set of 500 cases and 535 controls using the Sequenom MassARRAY iPLEX platform. Details of the subjects used in the discovery and replication stages of the study are provided in the Online Methods.
We used a multidimensional scaling analysis of an identity-bystate (IBS) sharing matrix of all individuals plus HapMap samples to assess population ancestry (Supplementary Fig. 1) . After applying quality-control measures and excluding subjects with non-European ancestry, genotypic data in the discovery group were available for 294,663 SNPs in 692 cases and 1,001 controls. Association testing of the discovery stage data was performed using a stratified CochranMantel-Haenszel (CMH) test in which samples were stratified according to their genome-wide IBS-sharing similarity. A quantile-quantile plot comparing the observed and expected distributions of −log 10 of P found by the CMH test showed some evidence for inflation of the test statistics given the multiple nationalities of PDB cases (genomic inflation factor 10 λ = 1.096; Supplementary Fig. 2) . To exclude the possibility of false positive association due to hidden population substructure, the observed test statistics were corrected using the genomic control method 10 . Six SNPs showed genome-wide significant associations with PDB after Bonferroni correction for multiple testing (Fig. 1) . Three were located within a 14-kb region of chromosome 1p13.3 (rs10494112, rs499345 and rs484959), one was located on chromosome 10p13 (rs1561570) and two were located within a 22-kb region of chromosome 18q21.33 (rs2957128 and rs3018362; Table 1 , Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone l e t t e r s Table 1) . We then used genotype data from HapMap to impute SNPs located within 1.0 Mb of the six SNPs which reached genome-wide significance. Association testing of imputed SNPs revealed several variants with genome-wide significance located close to the six genotyped significant SNPs identified from stage 1 (Fig. 2) . The imputed SNPs showed a slightly stronger association signal than the genotyped markers due to the conservative nature of the stratified CMH test used to analyze the genotyped markers as compared to the regression methods used to test imputed markers.
In total, 76 SNPs with P values of 1 × 10 −4 or less were identified in the discovery dataset (Supplementary Table 2 ). From these, we selected those SNPs with P < 1.0 × 10 −6 and also those with P < 1.0 × 10 −5 in which an additional SNP within 50 kb attained a P value of 1.0 × 10 −3 or less for further analysis in the replication group. Following application of quality-control measures on the replication dataset, genotype data were obtained for 481 cases and 520 controls for the 16 selected SNPs (Supplementary Table 3 ). Eight SNPs showed significant association with PDB in the replication stage after correction for multiple testing (P < 3 × 10 −3 ), resulting in the identification of eight SNPs for which the P values attained genome-wide significance in the combined dataset (Supplementary Table 3 ). The distribution of minor alleles and the direction of associations were similar in both the discovery and replication datasets ( Table 1 and  Supplementary Table 3) . Although all samples used in the replication stage were from individuals of European ancestry, confounding due to population substructure is possible given the multiple nationalities of the replication cohorts. To address this issue, we tested for association in replication samples from individuals of British descent only (256 cases and 488 controls) using the CMH test. This yielded results that were qualitatively similar to those obtained from the entire replication cohort (Supplementary Table 4 ). Linkage disequilibrium (LD) patterns in the associated regions were also similar across the study samples and were similar to those observed in HapMap CEU samples (Supplementary Fig. 3) . Furthermore, the distribution of allele frequencies for SNPs showing genome-wide significant association to PDB was broadly similar across individuals in this study when grouped by origin (Supplementary Table 5) , and the replicated hits were not located in genomic regions with known geographic variation among European populations 11, 12 . This indicates that the associations reported here are unlikely to be confounded by population substructure.
Significant association with PDB was observed on chromosome 1p13.3 for three SNPs (rs10494112, rs499345 and rs484595); the strongest signal was with rs484959 (combined P = 5.38 × 10 −24 ; Table 1 and Supplementary Table 1 ). These SNPs were weakly correlated (r 2 < 0.36) with other genotyped SNPs and are located in a 14-kb LD block 87 kb upstream of CSF1 (Fig. 2) . Another gene (EPS8L3) is located 47 kb further upstream but is separated from the associated SNPs by two recombination hot spots (Fig. 2) , making it a less likely candidate.
Stepwise regression analysis that adjusted for population clusters and accounted for the genotypic additive effect of the three SNPs showed strong evidence for independent association with rs484959 (P = 4.7 × 10 −10 ) and rs10494112 (P = 9.28 × 10 −3 ) as compared to rs499345 (P = 0.80; Supplementary Table 6 ). This is not surprising, as rs499345 is correlated with rs10494112 (r 2 = 0.61) but rs484959 and rs10494112 are not (r 2 = 0.21; Supplementary Fig. 3 ). An analysis of haplotypes formed by these three SNPs did not show a stronger association than an analysis of the individual SNPs (Supplementary Table 7) . CSF1 encodes macrophage colony-stimulating factor (M-CSF), which is a strong functional candidate for PDB susceptibility because it has a critical role in osteoclast formation and survival 13, 14 . Furthermore, loss-offunction mutations in rodent Csf1 cause osteopetrosis due to failure of osteoclast differentiation 15, 16 , whereas clinical studies have shown that individuals with PDB have increased serum levels of M-CSF 17 .
A second locus showing significant association with PDB was situated on chromosome 10p13. Three SNPs (rs1561570, rs825411 and rs2095388), all located within a 30-kb region, were analyzed in both stages of the study and the strongest signal was observed for rs1561570 l e t t e r s (combined P = 6.09 × 10 −13 ; Table 1 and Supplementary Table 3) . These three SNPs are weakly correlated with other genotyped SNPs (highest r 2 < 0.37). rs825411 is not in LD with rs1561570 (r 2 = 0.04) (Supplementary Fig. 3 ) but did attain borderline genome-wide significance (P = 7.82 × 10 −8 ) and appeared to have an independent association with PDB as revealed by regression analysis accounting for the genotypic additive effect of rs1561570 (P = 2.23 × 10 −9 ) and rs825411 (P = 5.15 × 10 −6 ; Supplementary Table 6) . Haplotype analysis showed a stronger association signal for alleles formed by both rs1561570 and rs825411 combined as compared to a single-SNP analysis, with the risk haplotype 'TC' showing the strongest association (P = 2.50 × 10 −17 , OR = 1.67; Supplementary Table 7) . The third SNP (rs2095388) showed no significant association with PDB in the combined analysis (P = 3.08 × 10 −6 ; Supplementary Table 3) and had no independent effect after accounting for rs1561570 and rs825411 in the analysis (P = 0.14; Supplementary Table 6 ).
The 10p13 locus is marked by two recombination hot spots and contains only one known gene, OPTN (Fig. 2) . It is interesting to note that this region of chromosome 10p13 has been previously linked to familial PDB but the causal gene within this region has not been identified 6 . It is therefore possible that the risk haplotype could be tagging rare allele(s) within OPTN that markedly increase susceptibility to PDB. In this regard, there have been other reports in which genome-wide association studies have identified common variants that are associated with diseases in which the associated variants lie within regions previously mapped by linkage analysis. Examples include variants associated with amyotrophic lateral sclerosis 18 and Crohn's disease 19 . Alternatively, the risk haplotype could be tagging another common susceptibility variant within the gene. Further studies will be required to investigate these possibilities. OPTN, which encodes optineurin, is a new candidate gene for PDB. Mutations in OPTN have been linked to glaucoma 20 , but until now, OPTN has not been implicated in regulating bone metabolism. Optineurin is a ubiquitously expressed cytoplasmic protein 21 that contains a ubiquitinbinding domain, similar to that present in the protein NEMO. Optineurin negatively regulates TNF-α-induced NF-κB activation by interacting with ubiquitylated RIP proteins 22 . Furthermore, a putative NF-κB binding site has been identified in the OPTN promoter 23 , and studies have shown that optineurin interacts with myosin VI, suggesting it plays a role in vesicular trafficking between the Golgi apparatus and plasma membrane 24 . This is of interest because mutations affecting the VCP protein, which is also involved in vesicular trafficking, cause inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD) syndrome 25 . Taken together, these data indicate that optineurin may have a hitherto unrecognized role in regulating bone metabolism through its effects on NF-κB signaling and/or vesicular trafficking.
The third region showing a significant association with PDB was located on chromosome 18q21.33 near TNFRSF11A, which encodes the receptor activator of NF-κB (RANK). Four SNPs within a 300-kb region reached genome-wide significance in the combined analysis (rs663354, rs2980996, rs2957128 and rs3018362). Regression analysis accounting for the genotypic-additive effect of the four SNPs showed that only rs2957128 (P = 0.047) and rs3018362 (P = 0.022) had independent effects (Supplementary Table 6 ). Analysis of haplotypes formed by alleles of rs2957128 and rs3018362 showed that a risk haplotype ' AA' was consistently over-represented in PDB cases compared with controls in the combined sample of cases and controls (P = 8.71 × 10 −14 , OR = 1.55; Supplementary Table 7) . These two SNPs are moderately correlated (r 2 = 0.55) and are located in adjacent LD blocks about 5 kb downstream of TNFRSF11A (Fig. 2c) .
The TNFRSF11A gene product RANK plays a critical role in osteoclast differentiation and function. Mice with targeted disruption of Tnfrsf11a exhibit severe osteopetrosis due to complete absence of osteoclasts 26 , and loss-of-function mutations in TNFRSF11A cause osteoclast-poor osteopetrosis in humans 27 . Mutations affecting the signal peptide region of RANK cause the PDB-like syndromes of familial expansile osteolysis, early-onset familial PDB and expansile skeletal hyperphosphatasia [28] [29] [30] . Mutations of TNFRSF11A have not so far been identified in individuals with classical PDB 28, 31 , although this region of chromosome . Genotyped SNPs were tested using stratified CMH tests; imputed SNPs were tested using a regression analysis based on imputed allelic dosage and adjusting for population clusters. SNPs reaching genome-wide significance are indicated with red text. LD plots for the indicated regions are based on HapMap CEU release 22 showing LD blocks depicted for alleles with MAF > 0.05 using the r 2 coloring scheme of Haploview 37 . The blue arrows indicate known genes in the region; possible recombination hot spots (>20 cM/Mb) are shown as green arrows on the LD plots. l e t t e r s 18q22 has been linked to PDB in some families 32 . It is also interesting to note that rs3018362 and rs884205, located downstream of TNFRSF11A, have recently been associated with bone mineral density and fracture risk [33] [34] [35] . The allele of rs3018362 that was associated with PBD was also associated with reduced bone mineral density, raising the possibility that this allele may be associated with increased bone turnover. rs884205 was not directly genotyped in our study, but it is moderately correlated with both rs3018362 (r 2 = 0.53) and rs2957128 (r 2 = 0.52). Imputation analysis showed evidence for association of rs884205 with PDB (imputed P value = 5.93 × 10 −11 ), confirming the importance of TNFRSF11A in the genetic regulation of bone metabolism. The three loci on chromosomes 1p13, 10p13 and 18q21 identified in this study appear to have independent roles, as we found no evidence to suggest that the associated SNPs within these loci interacted with each other to influence susceptibility to PDB (P > 0.33 for all interlocus pairwise interactions; Supplementary Table 8) . These data are consistent with a multiplicative model for association with PDB. The cumulative population attributable risk for the SNPs showing independent association with PDB was 70%. Additionally, the risk of PDB increased with an increasing number of risk allele scores (OR per-risk allele = 1.34, 95% CI 1.29-1.40, P = 5.81 × 10 −45 ), with individuals carrying ten or more risk alleles having a sixfold increase in PDB risk compared to those with the median number of risk alleles ( Table 2) .
It is likely that other genomic regions also contribute to PDB because the present study was powered only to detect variants with a moderate effect size (risk allele OR > 1.6). A quantile-quantile plot showing the distribution of P values after removal of all genome-wide significant SNPs and correlated markers showed an excess in the number of SNPs with low P values compared to what is expected by chance (Supplementary Fig. 2 ). For example, we observed 19 SNPs with P < 1 × 10 −5 compared to the expected 3, suggesting that other risk variants with a modest effect remain to be identified. These may include variants located on chromosomes 3p24, 8q22, 10q24 and 14q32, which did not reach genome-wide significance but could be considered suggestively associated with PDB (combined P < 1 × 10 −5 ; Supplementary Table 3) . Of particular interest is the 14q32 locus containing RIN3, encoding Ras interaction/interference protein 3, which is involved in vesicular trafficking 36 and could be important in osteoclast function.
In summary, we have demonstrated that common genetic variants at loci close to CSF1, OPTN and TNFRSF11A are independently associated with PDB. Further studies are now warranted to explore the mechanisms responsible for these associations.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website. a Risk allele score of the six SNPs showing independent association with PDB in the combined dataset (chr.1: rs10494112, rs484959; chr. 10: rs1561570 and rs825411; chr. 18: rs2957128 and rs3018362). Allele scores were normally distributed in cases and controls. Individuals carrying low-frequency scores (allele scores labeled 0 and 1 and 11 and 12) were combined together. b ORs are relative to the median number of risk alleles in the controls (five risk alleles).
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Study subjects. The genome-wide association study was conducted in a discovery sample of 750 cases of predominantly British descent with clinical and radiological evidence of PDB in whom mutations of the SQSTM1 gene had been excluded by DNA sequencing. These comprised subjects who had participated in the PRISM study (n = 597), a randomized trial of two different treatment strategies for PDB 38 ; clinic-based subjects from the UK with sporadic PDB (n = 55); and subjects with a family history of PDB derived from the UK (n = 20), Australia (n = 66), New Zealand (n = 8) and Italy (n = 4). Details of the 1,002 control subjects have previously been described 9 ; in brief, they comprised healthy subjects of Scottish descent with no clinical evidence of PDB. For the replication study, we conducted genotyping in an additional 500 PDB cases without SQSTM1 mutations who were diagnosed according to standard techniques. These comprised subjects with sporadic PDB who had been recruited from hospital clinics in the UK (n = 226), Italy (n = 20) and Spain (n = 200); subjects with sporadic PDB who had participated in the PRISM study (n = 43); and subjects with a positive family history of PDB who had been recruited from hospital clinics in Australia (n = 10) and the UK (n = 1). The 535 replication controls comprised subjects from the UK who had been referred for investigation of osteoporosis but who had been found to have normal bone density on examination by dual energy X-ray absorptiometry (n = 248), spouses of participants of the PRISM study who were not known to be affected by PDB (n = 252) and clinic-based controls from Spain (n = 35). All study participants were of European descent. The studies were approved by ethics review committees at the relevant institutions and all participants provided informed consent. The discovery sample had 96% power to detect disease-associated alleles with MAF = 0.2 and a genotype relative risk of 1.6, assuming a multiplicative model and a disease with population prevalence of 2%.
Stage 1 genotyping and quality control. Genotyping of PDB cases was performed at the genetics core of the Wellcome Trust Clinical Research Facility using Illumina HumanHap300-Duo BeadChip v2. Genotyping of the controls had been previously performed by Illumina Inc. using HumanHap300 v1 and HumanHap240S arrays 9 .
Genotypes for cases and controls were called using BeadStudio v3.2 (Illumina, Inc.) by following the manufacturer's recommended protocol. Genotype data for control subjects were provided after applying the quality-control measures described previously 9 . For the cases, we used a no-call threshold of 0.15 in BeadStudio and qualitycontrol metrics such as cluster separation, AB T mean (the mean normalized theta values of the heterozygote cluster) and AB R mean (the mean normalized intensity of the heterozygote cluster) to exclude badly performing SNPs. Samples with a call rate of less than 90% were excluded (n = 30). The data were then subjected to further quality-control measures using PLINK 39 to exclude SNPs with a call rate of less than 95%, those with Hardy-Weinberg equilibrium P values of less than 1.0 × 10 −4 in controls and those with a minor allele frequency of less than 1%. This left a total of 294,663 SNPs common to cases and controls with at least 95% call rates in each set. Samples with excess heterozygosity (one case), non-European ancestry (21 cases and one control) and related subjects (six cases) were excluded before analysis, leaving a final total of 692 cases and 1,001 controls with an average (± standard deviation) genotype call rate of 99.63 ± 1.0. The genotype cluster plots for all SNPs showing association with PDB at P < 1.0 × 10 −4 were visually inspected in BeadStudio. Population ancestry was determined using multidimensional scaling analysis of the IBS distances matrix of all individuals after combining genotype data from the HapMap project ( 40 and those with r 2 > 0.2 within a 150-SNP window. SNPs with call rate <99%, MAF <5% and Hardy-Weinberg equilibrium P <1.0 × 10 −4 in cases or controls were also excluded, leaving a total of 63,528 SNPs. The genome-wide average IBS distances matrix for all pairs of individuals was then calculated based on the total 63,528 SNPs using PLINK and was then used for multidimensional scaling analysis. Supplementary Figure 1 is a plot of the first two components of the multidimensional scaling analysis showing three clusters corresponding to the CEU, CHB with JPT, and YRI samples, with the majority of cases and controls located within the European CEU cluster. We identified 21 cases and one control as outliers from the CEU cluster, and these were excluded from further analysis. Based on genome-wide IBS distance, we identified five identical pairs (IBS distance >99%) and one related pair (IBS distance >85%) of samples from the cases cohort; the sample with the lowest call rate was excluded from each pair before further analysis. 42 in which the imputed allelic dosage was used to account for uncertainty in imputed genotypes.
Statistical analysis. Statistical analyses were performed using PLINK (Version 1.07) 39 .
In stage 1, genotyped SNPs were tested for association with PDB using a stratified CMH test. Samples were stratified based on their genome-wide IBS similarity so that individuals assigned to one cluster were not genetically different (P > 0.001, obtained from a pairwise population concordance test). The quantile-quantile plot and genomic control factor (λ) were used to assess overdispersion of the test statistics and were calculated using the statistical package R version 2.7.2 (see URLs) based on the 90% least significant SNPs as described previously 10 . Stepwise logistic regression was used to test for independent effects of an individual SNP, where the allelic dosage of the conditioning SNP was entered as a covariate in the regression model along with the population clusters identified by IBS-sharing analysis described above in order to adjust for population substructure. Haplotype analysis was performed by logistic regression, which looked at the presence or absence of the test haplotype and included the population clusters as a covariate in the model. Haplotypes were phased using the expectation-maximization algorithm implemented in PLINK, and only haplotypes with a frequency of ≥1% were analyzed. The cutoff point for genome-wide significance was set as P < 1.7 × 10 −7 (0.05/294,663 total SNPs) for stage 1, and P < 3 × 10 −3 (0.05/16 total SNPs) for the replication stage. For the combined analysis, we set the threshold for significance as P < 5 × 10 −8 as recently proposed 43 . The replication and combined datasets were analyzed as described above except that the replication dataset was considered as a separate cluster when population clusters were used in a stratified CMH test or as a covariate in logistic regression models. The population attributable risk (PAR) for markers showing association with PDB was calculated according to the following formula:
where p is the frequency of the risk allele in controls and OR is the risk allele odds ratio. The cumulative PAR was calculated as follows:
where n is the number of variants and PAR i is the individual PAR for the i th SNP.
URLs. R, http://www.r-project.org/.
